Patients with higher SAMD9 expression exhibited shorter OS in Kaplan-Meier analyses in all glioma and LGG (Figure 3Ap < 0.0001; Figure 3Bp < 0.0001). This evidence concerns the gene SAMD9 and central nervous system cancer.